3,524 results match your criteria Prolactinoma


[Differential diagnosis and treatment of pituitary adenomas].

HNO 2019 Feb 21. Epub 2019 Feb 21.

Klinik für Neurochirurgie, Universität Ulm, Albert-Einstein-Allee 23, 89075, Ulm, Deutschland.

Pituitary adenomas are among the most common primary brain tumors. These tumors can produce all hormones of the anterior pituitary and thus cause endocrine diseases. Compression of the pituitary gland, the surrounding cranial nerves, or brain structures can lead to hypopituitarism, cranial nerve deficits, or diverse neurological symptoms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00106-019-0629-3DOI Listing
February 2019

Glioblastoma and prolactinoma: a rare simultaneous occurrence.

J Surg Case Rep 2019 Feb 8;2019(2):rjz030. Epub 2019 Feb 8.

Department of Neurosurgery, King Abdualziz Medical City, Riyadh, Saudi Arabia.

The simultaneous development of two or more primary central nervous system (CNS) tumors of different cell types represents 0.9% of all diagnosed CNS tumors. To the best of our knowledge, the simultaneous occurrence of glioblastoma and pituitary adenomas has been reported four times in the English literature, with only two cases harboring prolactinoma and glioblastoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jscr/rjz030DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368138PMC
February 2019

Diagnosis and treatment of prolactinomas.

Expert Rev Endocrinol Metab 2009 Mar;4(2):135-142

b 3rd Department of Medicine, 1st Medical Faculty, U nemocnice 1, 128 02 Praha 2, Czech Republic.

Prolactinomas account for approximately 40% of all pituitary adenomas. Hyperprolactinemia causes hypogonadism, infertility and galactorrhea. Macroprolactinomas may cause signs of local expansion, such as headache, visual field defects and paresis of oculomotor nerves during suprasellar and parasellar extensions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17446651.4.2.135DOI Listing

Is prolactin involved in the evolution of atherothrombotic disease?

Expert Rev Endocrinol Metab 2012 May;7(3):345-361

f INSERM, Unit 845, Faculty of Medicine, Research Center in Growth and Signaling, Team 'PRL/GH Pathophysiology', University Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine Necker, Paris, France.

Cardiovascular diseases (CVDs) account for approximately 30% of all deaths globally. The most important cause of CVD is atherothrombosis, in other words, narrowing of the arteries as a result of the deposition of cholesterol and other lipoid substances within the arterial wall. Several endocrine disorders have been linked to this pathological state. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/eem.12.23DOI Listing

Prolactin and alteration of fertility.

Ceska Gynekol 2018 ;83(3):232-235

Aim: Physiology and pathology of prolactin production, clinical consequences.

Design: Review.

Setting: Reprogenesis International, Brno. Read More

View Article

Download full-text PDF

Source
January 2018
3 Reads

The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas.

Front Endocrinol (Lausanne) 2018 22;9:768. Epub 2019 Jan 22.

Department of Neurosurgery, School of Medicine, Jinling Hospital, Nanjing University, Nanjing, China.

Dopamine agonists such as bromocriptine and cabergoline are the predominant treatment drugs for prolactinoma by inhibiting prolactin secretion and shrinking tumor size. However, the pathways of either dopamine or its agonists that lead to the death of cells are incompletely understood and some are even conflicting conclusions. The main aim of this paper is to review the different pathways of dopamine and its agonists in prolactinomas to help to gain a better understanding of their functions and drug resistance mechanisms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fendo.2018.00768DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357924PMC
January 2019
1 Read

Clinical characteristics and surgical outcome of prolactinoma in patients under 14 years old.

Medicine (Baltimore) 2019 Feb;98(6):e14380

Department of Neurosurgery, Peking Union Medical College Hospital, Peking Union Medical College.

Prolactinoma is one of the most common pituitary tumors, but relatively uncommon in patients under 14 years old. Surgery is the second-line treatment for prolactinoma when patients show resistance or intolerance to medical therapy. There are only a few published series of children who underwent surgery treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000014380DOI Listing
February 2019
2 Reads
5.723 Impact Factor

[Clinical and functional characteristics of giant pituitary adenomas in the population of patients in the Moscow region].

Zh Vopr Neirokhir Im N N Burdenko 2018 ;82(6):76-81

Moscow Regional Researh and Clinical Institute, Moscow, Russia.

Benign pituitary tumors are the most common sellar neoplasms. Lesions larger than 39 mm in the maximum dimension are called giant. They are rare, and, therefore, there are few data on the clinical and morphological features of giant pituitary tumors with different hormonal activity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.17116/neiro20188206176DOI Listing
January 2018
1 Read

Metabolomics-A Promising Approach to Pituitary Adenomas.

Front Endocrinol (Lausanne) 2018 17;9:814. Epub 2019 Jan 17.

6th Department of Medical Sciences, Department of Endocrinology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.

Metabolomics-the novel science that evaluates the multitude of low-molecular-weight metabolites in a biological system, provides new data on pathogenic mechanisms of diseases, including endocrine tumors. Although development of metabolomic profiling in pituitary disorders is at an early stage, it seems to be a promising approach in the near future in identifying specific disease biomarkers and understanding cellular signaling networks. To review the metabolomic profile and the contributions of metabolomics in pituitary adenomas (PA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fendo.2018.00814DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345099PMC
January 2019
6 Reads

[Unilateral visual loss revealing nercotic prolactinoma].

J Fr Ophtalmol 2019 Feb 22;42(2):e79-e82. Epub 2019 Jan 22.

Service d'ophtalmologie, Hôpital militaire d'instruction Mohammed V, Faculté de médecine et de pharmacie, université Mohammed V-Rabat-Maroc, Rabat Maroc.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jfo.2018.05.013DOI Listing
February 2019
1 Read

Status epilepticus induced by treatment with dopamine agonist therapy for giant prolactinoma: a case report.

J Med Case Rep 2019 Jan 20;13(1):18. Epub 2019 Jan 20.

Department of Neurosurgery, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan.

Background: Dopamine agonists are the standard first-line medical therapy for prolactinoma. We report a rare case of giant prolactinoma with a first epileptic seizure due to rapid reduction of the tumor as a complication of dopamine agonist therapy.

Case Presentation: A 27-year-old Japanese man presented to our institution with a history of visual disturbance for 1 year and general fatigue for 3 months. Read More

View Article

Download full-text PDF

Source
https://jmedicalcasereports.biomedcentral.com/articles/10.11
Publisher Site
http://dx.doi.org/10.1186/s13256-018-1939-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6339691PMC
January 2019
7 Reads

Pituitary adenomas in patients with multiple endocrine neoplasia type 1: a single-center experience in China.

Pituitary 2019 Jan 14. Epub 2019 Jan 14.

Department of Endocrinology, Peking Union Medical College Hospital, Beijing, 100730, China.

Purpose: To explore the clinical characteristics of pituitary adenomas in patients with MEN1 and to summarize treatment strategies for MEN1 in a Chinese population.

Methods: We retrospectively analyzed 54 MEN1 patients with pituitary adenomas diagnosed at Peking Union Medical College Hospital from March 2003 to January 2017. Clinical data, laboratory testing results, treatments of involved glands and treatment responses were collected and analyzed. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11102-019-00939-x
Publisher Site
http://dx.doi.org/10.1007/s11102-019-00939-xDOI Listing
January 2019
13 Reads
2.222 Impact Factor

Effect of Everolimus in Treatment of Aggressive Prolactin-Secreting Pituitary Adenomas.

J Clin Endocrinol Metab 2019 Jan 8. Epub 2019 Jan 8.

Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, USA.

Context: Aggressive prolactin-secreting pituitary adenomas that are resistant to conventional therapy with dopamine agonists, surgery, and radiation pose a therapeutic challenge. The mTOR inhibitor everolimus is approved to treat neuroendocrine tumors (NETs) and co-treatment with the somatostatin receptor ligand octreotide improved median progression free survival in patients with metastatic pancreatic NETs.

Case Description: We describe off-label everolimus treatment of a prolactinoma (PRLoma) refractory to cabergoline, repeat surgical resection and radiation therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/jc.2018-02461DOI Listing
January 2019
4 Reads

Hormone Replacement Therapy in Cancer Survivors - Review of the Literature.

Pathol Oncol Res 2019 Jan 8. Epub 2019 Jan 8.

Department of Obstetrics and Gynecology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

Rapid advance in oncology leads to increasing survival of oncologic patients. More and more of them live long enough to reach either the natural age of menopause or, as a side effect of their oncotherapy, experience the cessation of gonadal function, leading to premature ovarian insufficiency, with disturbing vasomotor symtoms and long-term negative cardiovascular and skeletal effects. Thus, an ever increasing number of cancer survivors search endocrinologic help in the form of hormone replacement therapy (HRT). Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12253-018-00569-x
Publisher Site
http://dx.doi.org/10.1007/s12253-018-00569-xDOI Listing
January 2019
5 Reads

PGAM5-CypD pathway is involved in bromocriptine-induced RIP3/MLKL-dependent necroptosis of prolactinoma cells.

Biomed Pharmacother 2019 Jan 3;111:638-648. Epub 2019 Jan 3.

Multidisciplinary Center for Pituitary Adenomas of Chongqing, Department of Neurosurgery, Xinqiao Hospital, Army Medical University, 183th Street of Shapingba District, Chongqing, 400037, China. Electronic address:

Bromocriptine, the most commonly used dopamine (DA) receptor agonists for prolactinoma, can effectively reduce tumor size of prolactinoma, but the mechanism was not fully understood. Apoptosis had been well-recognized to contribute to the tumor mass regression caused by bromocriptine. However, whether other types of non-apoptotic cell death involved in the bromocriptine-induced prolactinoma shrinkage had not been fully clarified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biopha.2018.12.128DOI Listing
January 2019
1 Read

Quality of life is significantly impaired in both secretory and non-functioning pituitary adenomas.

Clin Endocrinol (Oxf) 2019 Mar 15;90(3):457-467. Epub 2019 Jan 15.

Neuroendocrinology Clinic, Department of Endocrinology and Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, México.

Objective: To evaluate the quality of life (QoL) in patients with pituitary adenomas in comparison with healthy Mexican population QoL scores.

Design & Measurements: Cross-sectional study using the short form 36 questionnaire (SF-36) in 175 patients with pituitary adenomas grouped by adenoma subtype and disease activity, and compared them with the healthy Mexican population normative QoL scores.

Patients: A total of 44 patients with non-functioning pituitary adenomas (NFPA), 48 with acromegaly, 53 with prolactinomas and 30 with Cushing disease (CD) were enrolled in this study. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/cen.13915
Publisher Site
http://dx.doi.org/10.1111/cen.13915DOI Listing
March 2019
5 Reads

Prolactinomas Resistant to Treatment With Dopamine Agonists: Long-Term Follow-Up of Six Cases.

Front Endocrinol (Lausanne) 2018 13;9:625. Epub 2018 Nov 13.

Endocrinology Service, Brasilia University Hospital, Brasília, Brazil.

Prolactinomas are preferentially treated with dopamine agonists. However, a few adenomas are resistant to this treatment. To evaluate the characteristics of patients with resistance to dopamine agonists in the long-term. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fendo.2018.00625DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6277870PMC
November 2018
1 Read

Fertility after transsphenoidal surgery in patients with prolactinomas: A meta-analysis.

Clin Neurol Neurosurg 2019 Jan 1;176:53-60. Epub 2018 Dec 1.

Computational Neuroscience Outcomes Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; School of Pharmacy, MCPHS University, Boston, MA, USA(3). Electronic address:

Pituitary prolactinomas in women often lead to amenorrhea, galactorrhea, or infertility. The purpose of this study was to evaluate the effectiveness of transsphenoidal surgery (TSS) in restoring fertility in women with proloactinomas. A systematic search of the literature was conducted in accordance with PRISMA guidelines through 6/13/2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clineuro.2018.11.024DOI Listing
January 2019
2 Reads
1.248 Impact Factor

Giant prolactinoma, germline BRCA1 mutation, and depression: a case report.

J Med Case Rep 2018 Dec 6;12(1):360. Epub 2018 Dec 6.

Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar Universitário de São João, E.P.E., Alameda Prof. Hernâni Monteiro, 4200-319, Porto, Portugal.

Background: Giant prolactinomas are very rare pituitary tumors that may exhibit an aggressive behavior and present with a life-threatening condition.

Case Presentation: A 25-year-old white woman was admitted to our hospital with a headache, psychomotor retardation, reduced vision, and loss of autonomy in daily activities. Her past medical history was significant for having oligomenorrhea and a depressive syndrome since her mother's death. Read More

View Article

Download full-text PDF

Source
https://jmedicalcasereports.biomedcentral.com/articles/10.11
Publisher Site
http://dx.doi.org/10.1186/s13256-018-1890-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282289PMC
December 2018
13 Reads

Management of dopamine agonist-resistant prolactinoma.

Authors:
Dominique Maiter

Neuroendocrinology 2018 Nov 27. Epub 2018 Nov 27.


Dopamine agonists are usually very effective in the treatment of prolactinomas. Nonetheless, a subset of individuals does not respond satisfactorily to these agents and this resistance is characterized by failure to achieve normoprolactinaemia and a 30% or more reduction in maximal tumor diameter (in the case of macroprolactinoma) under maximally tolerated doses. Its overall prevalence is 20-30% for bromocriptine (BRC) and around 10% for cabergoline (CAB). Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/495775
Publisher Site
http://dx.doi.org/10.1159/000495775DOI Listing
November 2018
8 Reads

Direct Carotid Cavernous Fistula Due to Rupture of a Cavernous Carotid Aneurysm Embedded Within a Prolactinoma After Cabergoline Administration.

World Neurosurg 2019 Feb 19;122:495-499. Epub 2018 Nov 19.

Department of Neurosurgery, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.

Background: A small number of reports have described subarachnoid hemorrhage resulting from a ruptured aneurysm embedded within a prolactinoma. To the best of our knowledge, no reports have described an embedded carotid cavernous fistula. We report a patient with carotid cavernous fistula secondary to a ruptured internal carotid artery aneurysm embedded within a prolactinoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.wneu.2018.11.071DOI Listing
February 2019
10 Reads

Human Prolactinoma: A View of Protein-Protein Interaction Pattern.

Int J Endocrinol Metab 2018 Oct 6;16(4):e67332. Epub 2018 Aug 6.

Proteomics Research Center, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

The aim of this study was to identify the highly expressed genes in terms of interaction concept in Prolactinoma. The study was conducted by additional analysis of the available data from the GEO database. The online tool, GEO2R, was used to analyze the gene expression profile of GSE36314 dataset using the GPL8300 platform. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5812/ijem.67332DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6216114PMC
October 2018
1 Read

Screening of AIP Gene Variations in a Cohort of Turkish Patients with Young-Onset Sporadic Hormone-Secreting Pituitary Adenomas.

Genet Test Mol Biomarkers 2018 Nov 21. Epub 2018 Nov 21.

2 Division of Endocrinology and Metabolic Diseases, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University , Istanbul, Turkey .

Aims: Aryl hydrocarbon receptor-interacting protein (AIP) gene mutations have long been associated with apparently sporadic pituitary adenomas (PAs) with a prevalence range of 0-12%. The aim of this study was to evaluate the frequency of germline AIP variations in a large cohort of apparently sporadic PAs diagnosed before the age of 40 years, who did not exhibit hypercalcemia and/or MEN1 syndrome components during long-term follow-up.

Materials And Methods: A total of 97 patients, diagnosed with functional PAs ≤40 years old, composed of somatotropinoma (n = 55), prolactinoma (n = 25), and corticotrophinoma (n = 17), were recruited for this study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/gtmb.2018.0133DOI Listing
November 2018
13 Reads

Spontaneous preoperative pituitary adenoma resolution following apoplexy: a case presentation and literature review.

Br J Neurosurg 2018 Nov 19:1-6. Epub 2018 Nov 19.

a Department of Neurological Surgery , University of Miami Miller School of Medicine , Miami , FL , USA.

Purpose: We aim to more fully understand the incidence and natural history of spontaneously resolving non-functioning pituitary adenomas (NFPAs).

Methods: We report a case of spontaneous complete resolution of a NFPA revealed by preoperative magnetic resonance imaging. In addition, we searched all major databases and neurosurgery journals to perform a comprehensive literature review of all previously reported cases of spontaneously resolving NFPAs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/02688697.2018.1529737DOI Listing
November 2018
2 Reads

Association of prolactin receptor (PRLR) variants with prolactinomas.

Hum Mol Genet 2018 Nov 15. Epub 2018 Nov 15.

Academic Endocrine Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, OX3 7LJ, UK.

Prolactinomas are the most frequent type of pituitary tumors, which represent 10-20% of all intracranial neoplasms in humans. Prolactinomas develop in mice lacking the prolactin receptor (PRLR), which is a member of the cytokine receptor superfamily that signals via Janus kinase-2-signal transducer and activator of transcription-5 (JAK2-STAT5) or phosphoinositide 3-kinase-Akt (PI3K-Akt) pathways to mediate changes in transcription, differentiation and proliferation. To elucidate the role of the PRLR gene in human prolactinomas, we determined the PRLR sequence in 50 DNA samples (35 leucocyte, 15 tumors) from 46 prolactinoma patients (59% males, 41% females). Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/hmg/advance-article/doi/10.1093/hmg
Publisher Site
http://dx.doi.org/10.1093/hmg/ddy396DOI Listing
November 2018
11 Reads

Controversies in Breastfeeding.

Authors:
Riccardo Davanzo

Front Pediatr 2018 1;6:278. Epub 2018 Nov 1.

Division of Pediatrics and Neonatology, Department of Mother and Child Health, Ospedale Madonna delle Grazie, Matera, Italy.

When addressing the compatibility of breastfeeding with certain maternal conditions, we need to differentiate between "contraindication" and "obstacle." Failure to distinguish between the two confuses new mothers and their families, and engenders misconceptions about breastfeeding advice by health professionals. Health conditions that may simply impede the initiation and duration of breastfeeding are often wrongly referred to as true contraindications to breastfeed, under the assumption that they might harm the health of the mother and/or that of the nursing infant. Read More

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fped.2018.00278/
Publisher Site
http://dx.doi.org/10.3389/fped.2018.00278DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221984PMC
November 2018
8 Reads

Retrospective analysis of 52 patients with prolactinomas following endoscopic endonasal transsphenoidal surgery.

Medicine (Baltimore) 2018 Nov;97(45):e13198

Department of Neurosurgery, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi.

Background: Prolactinomas affect patients' quality of life and even endanger lives. The study aimed to investigate the effect of the endoscopic endonasal transsphenoidal approach (EETA) on 52 patients with prolactinomas.

Methods: A total of 52 patients with prolactinomas who had previously undergone EETA in the People's Hospital of Xinjiang Uygur Autonomous Region between January 2013 and December 2017 were retrospectively analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000013198DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6250442PMC
November 2018
7 Reads

The ERα membrane pool modulates the proliferation of pituitary tumours.

J Endocrinol 2018 Nov 1. Epub 2018 Nov 1.

A Torres, Centro de Microscopía Electrónica, Universidad Nacional de Córdoba, Facultad de Ciencias Médicas, - Consejo Nacional de Investigaciones Científicas Técnicas (CONICET) Instituto de Investigaciones en Ciencias de la Salud, Córdoba, Argentina.

The molecular mechanisms underlying the ERα nuclear/cytoplasmic pool that modulates pituitary cell proliferation have been widely described, but it is still not clear how ERα is targeted to the plasma membrane. The aim of this study was to analyse ERα palmitoylation and the plasma membrane ERα (mERα) pool, and their participation in E2-triggered membrane-initiated signalling in normal and pituitary tumour cell growth. Cell cultures were prepared from anterior pituitaries of female Wistar rats and tumour GH3 cells, and treated with 10nM of estradiol (E2). Read More

View Article

Download full-text PDF

Source
https://joe.bioscientifica.com/view/journals/joe/aop/joe-18-
Publisher Site
http://dx.doi.org/10.1530/JOE-18-0418DOI Listing
November 2018
5 Reads

Giant Prolactinoma in Men: Clinical Features and Therapeutic Outcomes.

Horm Metab Res 2018 Nov 5;50(11):791-796. Epub 2018 Nov 5.

Department of Endocrinology, Hospital Universitario Ramón y Cajal, Madrid, Spain.

The aim of the study was to evaluate the clinical features and long-term therapeutic outcome of giant prolactinoma (gPRLoma) in men and to compare them with those of a group of male patients with non-gPRL macroprolactinomas (non-gPRLomas). A retrospective and multicenter study of gPRLomas in men diagnosed in a 20-year period was performed. Clinical data and treatment outcome were registered. Read More

View Article

Download full-text PDF

Source
http://www.thieme-connect.de/DOI/DOI?10.1055/a-0752-0741
Publisher Site
http://dx.doi.org/10.1055/a-0752-0741DOI Listing
November 2018
22 Reads

[Improvement and effect analysis of a new neuroendoscopic trans-nasal-sphenoidal pituitary tumor resection approach].

Zhonghua Yi Xue Za Zhi 2018 Oct;98(37):3021-3024

Department of Neurosurgery, Center of Prolactinoma, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China.

To modify the individual neuroendoscopic surgical approach of pituitary tumors with specific imaging features, and to analyze the clinical outcomes. The clinical data of 116 patients with pituitary tumors who underwent surgical treatment at the pituitary tumor diagnosis and treatment center of Ruijin Hospital from April 2014 to December 2017 were collected, then the resection effects and complication rates of pituitary tumors from three different kinds of transsphenoidal approaches (e.g. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0376-2491.2018.37.015DOI Listing
October 2018
1 Read

MicroRNA-93 mediates cabergoline-resistance by targeting ATG7 in prolactinoma.

J Endocrinol 2018 Sep 1. Epub 2018 Sep 1.

Z Su, Neurosurgery, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.

To date, the management of dopamine agonist (DA)-resistant prolactinomas remains a major clinical problem. Previously, we determined that miRNA-93 expression increases in DA-resistant prolactinomas; however, the role of miRNA-93 in the DA resistance remains largely unexplored. Hence, this study aimed to investigate the susceptibility of tumor cells to cabergoline (CAB) and the autophagy changes in MMQ and GH3 cells after miRNA-93 overexpression or inhibition. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/JOE-18-0203DOI Listing
September 2018
2 Reads

Tumor suppressor miR-145-5p sensitizes prolactinoma to bromocriptine by downregulating TPT1.

J Endocrinol Invest 2018 Oct 28. Epub 2018 Oct 28.

Department of Histology and Embryology, Medical School of Sun Yat-sen University, No. 74, Zhongshan Road 2, Guangzhou, 510080, Guangdong, China.

Purpose: Prolactinoma is the most commonly seen secretory tumor of pituitary glands, which accounts for approximately up to 40% of total pituitary adenomas. Due to its high drug resistance, dopamine agonist, such as bromocriptine, has limited effect on the treatment of patients with prolactinoma. Recent discoveries have revealed that multiple miRNAs were involved in regulating drug resistance. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40618-018-0963-4
Publisher Site
http://dx.doi.org/10.1007/s40618-018-0963-4DOI Listing
October 2018
14 Reads

No evidence of adverse fertility and pregnancy outcomes in patients with unrecognized and untreated multiple endocrine neoplasia type 1.

Clin Endocrinol (Oxf) 2019 Feb 14;90(2):312-319. Epub 2018 Nov 14.

School of Medicine, Department of Diabetes and Endocrinology, Royal Hobart Hospital, University of Tasmania, Hobart, Tasmania.

Objective: Literature concerning the impact of multiple endocrine neoplasia type 1 (MEN 1) on fertility is limited to case reports despite the early onset of endocrinopathies, such as primary hyperparathyroidism and prolactinoma, that may impact fertility. This study describes the impact of unrecognized and untreated MEN 1 on fertility and pregnancy outcomes in a multigenerational cohort of the Tasman 1 MEN 1 kindred.

Methods: All MEN 1 positive (MEN 1 , n = 63) and MEN 1 negative (MEN 1 , n = 75) descendants born between 1825 and 1951 of a common founder. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/cen.13890
Publisher Site
http://dx.doi.org/10.1111/cen.13890DOI Listing
February 2019
11 Reads

Management of prolactinoma: a survey of endocrinologists in China.

Endocr Connect 2018 Oct;7(10):1013-1019

Division of Endocrinology and Metabolism, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.

Objective To assess the current management of prolactinoma among endocrinologists in China. Methods An online survey of a large sample of endocrinologists was conducted in China. The questionnaire included 21 questions related to controversial issues about the management of prolactinomas. Read More

View Article

Download full-text PDF

Source
https://ec.bioscientifica.com/view/journals/ec/7/10/EC-18-02
Publisher Site
http://dx.doi.org/10.1530/EC-18-0250DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198182PMC
October 2018
11 Reads

Coexistent Pituitary Adenoma with Rathke's Cleft Cyst: A Case Series.

J Assoc Physicians India 2018 03;66(3):42-6

Professor and Head of Department, Department of Endocrinology, Seth GS Medical College, Mumbai, Maharashtra.

Objective: Co existent pituitary adenoma and Rathke's cleft cyst (RCC) is a rare entity. Purpose of this study is to describe the clinical presentation, imaging findings, and management of patients with this combination.

Methods: Retrospective review of records from a single tertiary care center for a period of three years [2009-2012]. Read More

View Article

Download full-text PDF

Source
March 2018
8 Reads

Prolactin, prolactin disorders, and dopamine agonists during pregnancy.

Hormones (Athens) 2018 Oct 19. Epub 2018 Oct 19.

Department of Obstetrics and Gynecology, Hadassah University Hospital, PO Box 12000, 91120, Jerusalem, Israel.

Pituitary disorders, and especially prolactinomas, are not common among pregnant women, though they tend to occur during a woman's years of fertility. The majority of prolactinoma patients present with infertility and menstruation dysfunction; however, prolactinomas are associated with potentially significant morbidity if they remain unrecognized and untreated. Herein, we survey the role of prolactin and prolactinomas in pregnancy while also outlining the therapeutic approach to prolactinoma during pregnancy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s42000-018-0071-zDOI Listing
October 2018
3 Reads

Nonalcoholic fatty liver disease with prolactin-secreting pituitary adenoma in an adolescent: A case report.

Medicine (Baltimore) 2018 Oct;97(42):e12879

Department of Pediatrics and Child Health, Kurume University School of Medicine, Kurume, Japan.

Rationale: Nonalcoholic fatty liver disease (NAFLD), among the commonest chronic liver disorders in children and adolescents, is considered a reflection of the current obesity epidemic in children and adults. This liver disease has been linked with various metabolic disorders, but not with prolactinoma (PRLoma).

Patient Concerns: A 13-year-old Japanese girl manifested obesity, serum transaminase and γ-glutamyltransferase elevations, and amenorrhea. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000012879DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6211884PMC
October 2018
2 Reads

Metformin inhibits growth and prolactin secretion of pituitary prolactinoma cells and xenografts.

J Cell Mol Med 2018 Dec 18;22(12):6368-6379. Epub 2018 Oct 18.

Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medicine Sciences & Peking Union Medical College, Beijing, China.

Metformin (MET) is a diabetes drug that activates AMP-activated protein kinase (AMPK), and is suggested to have anticancer efficacy. Here, we investigated the role of AMPK signalling in prolactinoma (PRLoma), with particular respect to MET and bromocriptine (BC) as a PRLoma treatment. We analysed AMPK phosphorylation, dopamine D2 receptor (D2R), and oestrogen receptor (ER) expression in both BC-sensitive and -resistant PRLoma samples; effects of the AMPK agonist MET (alone or with BC) on in vitro proliferation and apoptosis, xenograft growth and prolactin (PRL) secretion of BC-sensitive and -resistant cells, and ER expression in xenografts. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jcmm.13963DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237574PMC
December 2018
3 Reads

Evaluation of Hypothalamic-Pituitary-Adrenal Axis by the GHRP2 Test: Comparison With the Insulin Tolerance Test.

J Endocr Soc 2018 Aug 26;2(8):860-869. Epub 2018 Jun 26.

Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.

Context: GH-releasing peptide 2 (GHRP2) stimulates the hypothalamic-pituitary-adrenal axis (HPA) through the GH secretagogue receptor (GHSR) in the hypothalamus, in which ghrelin is a natural ligand. Therefore, the GHRP2 test (GHRP2T) could be used instead of the insulin tolerance test (ITT).

Objective: Can the GHRP2T replace the ITT for evaluation of HPA?

Design: The present retrospective study analyzed the clinical features and laboratory data from 254 patients admitted for evaluation of hypopituitarism who underwent both GHRP2T and ITT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/js.2018-00102DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055535PMC
August 2018
2 Reads

Pituitary Adenoma Apoplexy of the Orbit, Diagnosis, and Management With Presurgical Embolization.

Ophthalmic Plast Reconstr Surg 2018 Nov/Dec;34(6):e196-e197

Johns Hopkins University School of Medicine, Wilmer Eye Institute, Baltimore, Maryland, U.S.A.

Orbital invasion of pituitary adenomas has been previously reported. In this report, the authors describe a 71-year-old female with a prolactinoma that presented with invasion of and apoplexy within the orbit. The patient underwent exenteration, followed by rapid tumor recurrence and growth. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/IOP.0000000000001241DOI Listing
October 2018
2 Reads

Utility of N-Ammonia PET/CT to Detect Pituitary Tissue in Patients with Pituitary Adenomas.

Acad Radiol 2018 Oct 12. Epub 2018 Oct 12.

Department of Neurosurgery and Pituitary Tumor Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. Electronic address:

Rationale And Objectives: It is clinically essential, but sometimes challenging, to distinguish pituitary tissue from pituitary adenomas (PAs). It is helpful to avoid damage of pituitary tissue during management. We evaluated the ability of N-ammonia positron emission tomography (PET)/computed tomography (CT) to locate and distinguish pituitary tissue from PAs. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10766332183043
Publisher Site
http://dx.doi.org/10.1016/j.acra.2018.09.015DOI Listing
October 2018
9 Reads

Pasireotide: A potential therapeutic alternative for resistant prolactinoma.

Ann Endocrinol (Paris) 2018 Sep 25. Epub 2018 Sep 25.

Centre de référence maladies rares hypophysaires (HYPO), fédération d'endocrinologie, groupement hospitalier Est, hospices civils de Lyon, 69677 Bron, France; Faculté de médecine Lyon Est, université Lyon 1, 69372 Lyon, France; Inserm U1052, CNRS UMR5286, Cancer Research Centre of Lyon, 69372 Lyon, France. Electronic address:

Context: About 10% of prolactinomas are resistant to dopamine-agonists (DAs). The only alternatives for tumor and prolactin control are surgery or radiotherapy. While studies on first generation somatostatin analogs have shown no efficacy against prolactinomas, no study has been conducted on the new multireceptor-targeted somatostatin receptor ligand pasireotide, which presents high affinity for 5, 3, 2 and 1 receptor subtypes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2018.07.013DOI Listing
September 2018
1 Read

Endonasal Chiasmapexy Using Autologous Cartilage/Bone for Empty Sella Syndrome After Cabergoline Therapy for Prolactinoma.

World Neurosurg 2019 Jan 11;121:145-148. Epub 2018 Oct 11.

Department of Neurosurgery, Keio University School of Medicine, Sinjuku-ku, Tokyo, Japan.

Background: Visual field deterioration caused by secondary empty sella after cabergoline therapy for prolactinoma is a rare event. Chiasmapexy is performed to treat empty sella syndrome. Although various materials have been used for the elevation of the optic chasm, the most appropriate material remains to be established. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.wneu.2018.10.012DOI Listing
January 2019
3 Reads

DICER1 mutation and pituitary prolactinoma

Endocrinol Diabetes Metab Case Rep 2018 Sep 25;2018. Epub 2018 Sep 25.

Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK

A young woman carrying germline DICER1 mutation was discovered to have a pituitary microprolactinoma when she became amenorrhoic. The mutation was identified as a result of family screening following the early death of the patient’s daughter with ovarian cancer. The patient was in follow-up screening for thyroid disease, and investigations were initiated when she became amenorrhoic. Read More

View Article

Download full-text PDF

Source
https://edm.bioscientifica.com/view/journals/edm/2018/1/EDM1
Publisher Site
http://dx.doi.org/10.1530/EDM-18-0087DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169535PMC
September 2018
16 Reads

T2-weighted magnetic resonance imaging characterization of prolactinomas and association with their response to dopamine agonists.

Endocrine 2019 Feb 28;63(2):323-331. Epub 2018 Sep 28.

Department of Endocrinology, CHU Mont-Godinne-Dinant, Université catholique de Louvain, Yvoir, Belgium.

Purpose: Recent work supports the use of T2-weighted MRI intensity as a tool for treatment stratification in acromegaly. Our study aimed to establish if the pattern of T2 intensity could be a predictor of hormonal and/or tumoral response to dopamine agonists (DAs) in prolactinomas.

Methods: This was a retrospective study performed in two academic centers. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12020-018-1765-3
Publisher Site
http://dx.doi.org/10.1007/s12020-018-1765-3DOI Listing
February 2019
7 Reads

Ept7, a quantitative trait locus that controls estrogen-induced pituitary lactotroph hyperplasia in rat, is orthologous to a locus in humans that has been associated with numerous cancer types and common diseases.

PLoS One 2018 27;13(9):e0204727. Epub 2018 Sep 27.

McArdle Laboratory for Cancer Research, Department of Oncology, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, United States of America.

Pituitary adenoma is a common intracranial neoplasm that is observed in approximately 10% of unselected individuals at autopsy. Prolactin-producing adenomas, i.e. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0204727PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6160183PMC
September 2018
10 Reads

Multiple Endocrine Neoplasia Type 1: A Case Report With Review of Imaging Findings.

Ochsner J 2018 ;18(2):170-175

Department of Radiology, Ochsner Clinic Foundation, New Orleans, LA.

Background: Multiple endocrine neoplasia type 1 (MEN1) is a rare, autosomal dominant inherited syndrome caused by mutations in the MEN1 tumor suppressor gene. The diagnosis is defined clinically by the presence of 2 or more primary MEN1 tumors (parathyroid, anterior pituitary, and pancreatic islet). We describe the case of a patient who presented with classic history and imaging findings for MEN1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.31486/toj.17.0019DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6135292PMC
January 2018
3 Reads

Neurosurgical anesthesia for a pregnant woman with macroprolactinoma: A case report.

Medicine (Baltimore) 2018 Sep;97(37):e12360

Department of Anesthesiology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People's Republic of China.

Rationale: Being required to perform neurosurgery on a pregnant woman is rare, but occasionally unavoidable. In these cases, clinical anesthesiologists are confronted with conflicting information and few evidence-based guidelines.

Patient Concerns: Here, we describe the successful anesthetic management of a 24-week pregnant woman with macroprolactinoma who underwent endonasal transsphenoidal resection of pituitary adenoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000012360DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156042PMC
September 2018
4 Reads

Impulse control disorders in patients with prolactinoma receiving dopamine agonist therapy: a prospective study with 1 year follow-up.

Endocrine 2018 Dec 11;62(3):692-700. Epub 2018 Sep 11.

Department of Endocrinology and Metabolism, Cerrahpasa Medical School, Istanbul University, Istanbul, Turkey.

Objective: To assess prospectively the prevalence of impulse control disorders (ICD), psychiatric symptoms, and their clinical correlates in patients with prolactinoma receiving dopamine agonists (DA) in comparison to those with non-functioning pituitary adenomas (NFA) and healthy controls (HC).

Methods: A total of 25 patients with prolactinoma, 31 with NFA, and 32 HCs were included in the study. All patients and controls were screened for the presence of ICDs and other psychiatric disorders using revised version of Minnesota Impulsive Disorders Interview (MIDI-R), Barratt Impulsiveness Scale (BIS-11), Symptom Check List (SCL-90-R) questionnaire and Beck Depression Inventory (BDI), and Beck Anxiety Inventory (BAI). Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12020-018-1744-8
Publisher Site
http://dx.doi.org/10.1007/s12020-018-1744-8DOI Listing
December 2018
17 Reads

Familial Cancer Clustering in Patients with Prolactinoma.

Horm Cancer 2019 Feb 8;10(1):45-50. Epub 2018 Sep 8.

School of Medicine, University of Belgrade, Dr Subotic 8, Belgrade, 11000, Serbia.

People are at higher risk for malignancy as they get older or have a strong family history of cancer. This study aims to collect family history of cancer in a large cohort of patients with pituitary adenomas (PA) in outpatient clinic from years 2005-2017. Overall, 46. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12672-018-0348-3DOI Listing
February 2019
3 Reads